Amifostine (WR-2721) shortens the engraftment period of 4- hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support

4-Hydroperoxycyclophosphamide (4-HC), a commonly used marrow-purging agent, is active against many tumors, but is also toxic to normal marrow progenitors. Amifostine (WR-2721) is a sulfhydryl compound with chemoprotectant activity. Preclinical studies using suspensions of bone marrow and breast cancer cells demonstrated that ex vivo treatment with amifostine followed by 4-HC resulted in protection of marrow progenitors, with no compromise in the antitumor effect of 4-HC. This fact stimulated the development of a clinical trial. Bone marrow was harvested from 15 poor-prognosis breast cancer patients and randomly assigned to ex vivo treatment with amifostine followed by 4-HC (amifostine + 4-HC), or treatment with 4-HC alone. High-dose chemotherapy was then administered followed by infusion of the purged autologous bone marrow support (ABMS). Leukocyte engraftment, defined as a white blood cell count > or = 1 x 10(9)/L, was achieved in an average of 26 days for patients whose marrow was purged with amifostine + 4-HC versus 36 days for patients whose marrow was purged with 4-HC alone (P = .032). The average number of platelet transfusions (12 v 29; P = .017) and days of antibiotic therapy (28 v 40; P = .012) were significantly less for patients whose marrow was exposed to amifostine + 4-HC, compared with 4-HC alone. Unpurged backup marrow fractions were infused into three patients whose marrow was purged with 4-HC alone, because of inadequate marrow recovery. None of the patients who received amifostine + 4-HC-purged marrow required a backup marrow fraction. Complete remissions were achieved in 83% of patients with measurable disease, with no difference between the two cohorts. Forty- three percent of patients remained alive and progression-free at a mean of 13 months posttransplant. There was no significant difference in the rate or pattern of relapse for patients whose marrow was purged with amifostine + 4-HC compared with those whose marrow was purged with 4-HC alone. Ex vivo treatment of marrow with amifostine significantly shortens the time to marrow recovery, thereby reducing the risk of myelosuppressive complications in breast cancer patients receiving high- dose chemotherapy and 4-HC-purged ABMS. Since supportive care requirements are also significantly decreased, amifostine may reduce the cost of such therapy.     

Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa

Because free factor VIIa is inactivated only very slowly by a plasma concentration of antithrombin III (AT III) even in the presence of heparin, it has been assumed that AT III plays no significant role in regulating the initiation of tissue factor-dependent blood coagulation. However, in the present study, we present evidence that factor VIIa bound to tissue factor, unlike free factor VIIa, is readily inactivated by AT III in the presence of heparin. In a reaction mixture containing calcium ions and approximately equimolar concentrations of relipidated tissue factor (8.9 nmol/L) and factor VIIa (10 nmol/L), AT III (100 micrograms/mL) plus heparin (1 U/mL) inhibited 50% of the factor VIIa coagulant activity of the reaction mixture within 5 minutes. AT III/heparin was also shown to inhibit the catalytic activity towards factor X of factor VIIa/tissue factor complexes formed on monolayers of an ovarian carcinoma cell line (OC-2008) that constitutively expresses surface membrane tissue factor. AT III, even in the absence of exogenously added heparin, substantially inhibited the functional activity of factor VIIa/cell surface tissue factor complexes on intact monolayers. AT III alone and AT III/heparin, to a greater extent, also inhibited factor VIIa on "nonfunctional" factor VIIa/tissue factor complexes on intact monolayers, with resultant inhibition of their expression of factor VIIa/tissue factor catalytic activity toward factor X after cell lysis. The potential physiologic significance of these findings is discussed.     

Role of sympathetic nerve fibers in hemodynamic responses to stress in rats]

Hemodynamic responses to acute stress exposure were studied in normotensive control (C) and chronically sympathectomized (S) rats. Male Sprague-Dawley rats received daily sc injections of either saline (C) or guanethidine (S) from 1 to 13 weeks of age. Doppler flow probes were then implanted for the measurement of blood velocity in the sub-diaphragmatic aorta, superior mesenteric artery and distal aorta (hindquarters). After 10 days of recovery and 24 hours before the study, the caudal artery was cannulated. In the conscious freely moving rats, mean arterial pressure (MAP), heart rate (HR) and indices of regional blood flows and vascular conductances (G as blood flow/MAP ratio) were recorded beat to beat, before and during emotional stress (jet of air for 2 min). In basal conditions, mean values of MAP and HR were similar in C (107 +/- 2 mmHg; 399 +/- 8 bpm, n = 9) and S (106 +/- 3 mmHg; 384 +/- 12 bpm, n = 7) rats. The effects of stress on MAP, HR, aortic (AoG), mesenteric (MeG) and hindquarters (HqG) vascular conductances are expressed as percentage changes from baseline (delta): [table: see text] These results highlight the role of vascular sympathetic nerves in pressor responses and systemic and mesenteric vasoconstrictions induced by stress in the rat. They also indicate that vasodilatation in the hindquarters vascular bed is not secondary to withdrawal of sympathetic vasoconstrictor tone but rather to active phenomena which do not involve the stimulation of vascular beta 2-adrenoceptors by neuronal catecholamines nor the release of vasodilator cotransmitters from the sympathetic nerve endings.     

A granulocyte reactive monoclonal antibody, 1G10, identifies the Gal beta 1-4 (Fuc alpha 1-3)GlcNAc (X determinant) expressed in HL-60 cells on both glycolipid and glycoprotein molecules

1G10, a monoclonal IgM antibody that identifies a differentiation antigen on human granulocytes and a subpopulation of monocytes, was found to react specifically with glycosphingolipids bearing the Gal beta 1-4(Fuc alpha 1-3)GlcNAc hapten (X determinant). This carbohydrate determinant was found on both glycolipid and glycoprotein molecules isolated from HL-60 cells (a promyelocytic leukemia cell line). Thus, this highly conserved carbohydrate-defined determinant previously described on mouse embryonic and mouse and human carcinoma cells is also expressed as a tissue-specific differentiation antigen on normal human granulocytes.     

血浆纤溶酶原激活物抑制物1与胰岛素抵抗的相关性研究

目的：探讨血浆纤溶酶原激活物抑制物1（plasminogen activitor inhibitor one,PAI-1)活性及其基因启动子区4G／5G多态性与胰岛素抵抗综合征的关系。方法：应用等位基因特异性PCR扩增技术，对胰岛素抵抗综合征患者（160例）和对照组（90例）PAI－1 4G／5G多态位点的基因型进行检测，用发色底物法测血浆PAI－1活性。结果：（1）胰岛不抵抗综合综合患者PAI－1活性明显升高，空腹胰岛素，空腹血糖，甘油三酯与PAI－1活性升高密切相关（P＜0．01）。（2）对照组和胰岛素抵抗综合征患者，4G／5G基因型频率分别为0．52和0．48，两组比较无明显差异（P＞0．05），但胰岛素抵抗综合征不同基因型者PAI－1活性差异显著（P＜0．01），4G／4G基因型者PAI－1活性高于4G／5G和5G／5G基因型者（P＜0．01）。（3）血糖、甘油三酯对PAI－1活性的调节受基因型的影响。4G／4G基因型者血糖，甘油三酯与PAI－1活性密切相关（P＜0．01），而4G／5G和5G／5G基因型者血糖。甘油三酯与PAI－1活性无明显相关（P＞0．05）。（4）胰岛素对PAI－1活必的影响无基因型依赖性。结论：PAI－1活性升高是胰岛素抵抗综合征患进的特征之一，免疫反应性胰岛素，血糖，甘油三酯与PAI－1活性升高有关，血糖，甘油三酯对PAI－1活性的调节存在明显的基因型依赖性。     

The relationship of nasal disorders to lower respiratory tract symptoms and illness in a random sample of children.

We examined the relationship of nasal disorders, defined as frequent colds and sinus trouble, to lower respiratory tract symptoms in a random population of 718 children aged 4 to 11 years in East Boston, Massachusetts. Frequent colds were significantly associated with maternal smoking (odds ratio (OR) = 3.00; 95% confidence interval (CI) = 1.97, 4.58), and so was sinus trouble (OR = 4.73; 95% CI = 1.78, 12.51). After adjustment for maternal smoking, age and sex, frequent colds (OR = 2.88; 95% CI = 1.87, 4.42) and sinus trouble (OR = 4.95, 95% CI = 1.83, 13.39) remained significant predictors of lower respiratory tract symptoms in separate logistic regressions. If one restricted the cohort to the 513 children who also had personal smoking information and adjusted for this variable as well, the results for colds were unchanged (OR = 2.94; 95% CI = 1.78, 4.84) but the results for sinus trouble were now not statistically significant (OR = 2.30, 95% CI = 0.67, 7.94). We conclude that nasal disorders are associated with lower respiratory tract symptoms in children.     

Acetylesterase in lymphoblastic leukaemia associated with thymic enlargement

Focal cytoplasmic acetylesterase activity was sought in the malignant cells of 91 consecutive children with acute lymphoblastic leukaemia, of whom 10 had an anterior mediatstinal mass at diagnosis. This subgroup with thymic disease (TD) was characterized by hyperleucocytosis, the total leucocyte count being greater than 200 X 10(9)/1 in 6 patients. Furthermore, there was a significant association (P less than 0.025) between TD and the presence of leukaemic blast cells expressing a thymic phenotype, in the form of rosette formation with sheep erythrocytes. Focal cytoplasmic acetylesterase activity identified TD with a sensitivity of 20%, a specificity of 91%, a positive predictive value of 25%, a negative predictive value of 88% and a diagnostic accuracy of 81%. The demonstration of this feature by a simple cytochemical technique can be a useful component of the profile of investigations which are employed in the classification of acute lymphoblastic leukaemia.     

Alteration in insulin action: role of IRS-1 serine phosphorylation in the retroregulation of insulin signalling

Insulin resistance, when combined with impaired insulin secretion, contributes to the development of type 2 diabetes. Insulin resistance is characterised by a decrease in insulin effect on glucose transport in muscle and adipose tIssue. Tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1) and its binding to phosphatidylinositol 3-kinase (PI 3-kinase) are critical events in the insulin signalling cascade leading to insulin-stimulated glucose transport. Modification of IRS-1 by serine phosphorylation could be one of the mechanisms leading to a decrease in IRS-1 tyrosine phosphorylation, PI 3-kinase activity and glucose transport. Recent findings demonstrate that "diabetogenic" factors such as FFA, TNFalpha, hyperinsulinemia and cellular stress, increase the serine phosphorylation of IRS-1 and identified Ser307/612/632 as phosphorylated sites. Moreover, several kinases able to phosphorylate these serine residues have been identified. These exciting results suggest that serine phosphorylation of IRS-1 is a possible hallmark of insulin resistance in biologically insulin responsive cells or tIssues. Identifying the pathways by which "diabetogenic" factors activate IRS-1 kinases and defining the precise role of serine phosphorylation events in IRS-1 regulation represent important goals. Such studies may enable rational drug design to selectively inhibit the activity of the relevant enzymes and generate a novel class of therapeutic agents for type 2 diabetes.